Compare RCMT & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCMT | ELDN |
|---|---|---|
| Founded | 1971 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 150.7M | 166.4M |
| IPO Year | N/A | N/A |
| Metric | RCMT | ELDN |
|---|---|---|
| Price | $18.51 | $2.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $30.00 | $8.50 |
| AVG Volume (30 Days) | 47.0K | ★ 548.9K |
| Earning Date | 03-11-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | ★ $309,840,000.00 | N/A |
| Revenue This Year | $16.29 | N/A |
| Revenue Next Year | $6.92 | N/A |
| P/E Ratio | $10.72 | ★ N/A |
| Revenue Growth | ★ 13.70 | N/A |
| 52 Week Low | $13.18 | $1.35 |
| 52 Week High | $28.27 | $4.65 |
| Indicator | RCMT | ELDN |
|---|---|---|
| Relative Strength Index (RSI) | 27.81 | 49.31 |
| Support Level | $17.26 | $1.96 |
| Resistance Level | $21.41 | $2.22 |
| Average True Range (ATR) | 0.74 | 0.13 |
| MACD | -0.32 | -0.03 |
| Stochastic Oscillator | 3.86 | 20.08 |
RCM Technologies Inc is a provider of business and technology solutions designed to enhance and maximize the operational performance of its customers. It operates in three segments: Specialty Health Care, Engineering, and Life Sciences, Data and Solutions (LS&D). The company generates maximum revenue from the Specialty Health Care segment that provides staffing solutions including medical healthcare professionals, health information management professionals, nurses, paraprofessionals, physicians, and therapists. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Puerto Rico, the Philippines, and Europe.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.